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Trigger for Group A Streptococcal M1T1 Invasive Disease
Abstract
The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly invasive
human diseases. The transition from local to systemic infection occurs by an unknown mechanism;
however invasive M1T1 clinical isolates are known to express significantly less cysteine protease SpeB
than M1T1 isolates from local infections. Here, we show that in comparison to the M1T1 strain 5448, the
isogenic mutant ∆speB accumulated 75-fold more human plasmin activity on the bacterial surface
following incubation in human plasma. Human plasminogen was an absolute requirement for M1T1
strain 5448 virulence following subcutaneous infection of humanized plasminogen transgenic mice. S.
pyogenes M1T1 isolates from the blood of infected humanized plasminogen transgenic mice expressed
reduced levels of SpeB in comparison with the parental 5448 used as inoculum. We propose that the
human plasminogen system plays a critical role in group A streptococcal M1T1 systemic disease
initiation. SpeB is required for S. pyogenes M1T1 survival at the site of local infection, however, SpeB also
disrupts the interaction of S. pyogenes M1T1 with the human plasminogen activation system. Loss of
SpeB activity in a sub-population of S. pyogenes M1T1 at the site of infection results in accumulation of
surface plasmin activity thus triggering systemic spread.
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ABSTRACT

The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly
invasive human diseases. The transition from local to systemic infection occurs by an
unknown mechanism; however invasive M1T1 clinical isolates are known to express
significantly less cysteine protease SpeB than M1T1 isolates from local infections. Here,
we show that in comparison to the M1T1 strain 5448, the isogenic mutant ∆speB
accumulated 75-fold more human plasmin activity on the bacterial surface following
incubation in human plasma. Human plasminogen was an absolute requirement for M1T1
strain 5448 virulence following subcutaneous infection of humanized plasminogen
transgenic mice. S. pyogenes M1T1 isolates from the blood of infected humanized
plasminogen transgenic mice expressed reduced levels of SpeB in comparison with the
parental 5448 used as inoculum. We propose that the human plasminogen system plays a
critical role in group A streptococcal M1T1 systemic disease initiation. SpeB is required for
S. pyogenes M1T1 survival at the site of local infection, however, SpeB also disrupts the
interaction of S. pyogenes M1T1 with the human plasminogen activation system. Loss of
SpeB activity in a sub-population of S. pyogenes M1T1 at the site of infection results in
accumulation of surface plasmin activity thus triggering systemic spread.

Key words: Streptococcus pyogenes, SpeB, plasminogen.
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INTRODUCTION

Epidemic invasive group A Streptococcus (GAS, S. pyogenes) disease in the Western
World since the mid-1980s has been paralleled by the emergence of a globally
disseminated serotype M1T1 GAS clone (1). This M1T1 clone is associated with lifethreatening infections such as necrotizing fasciitis and streptococcal toxic shock syndrome
(2), whilst also causing uncomplicated infections in other patients (3). The mechanism that
triggers the transition from local to invasive infection by GAS M1T1 is unknown, however
epidemiologic studies have documented an inverse relationship between human invasive
disease and the expression of the streptococcal pyrogenic exotoxin B (SpeB) (4). SpeB is a
secreted cysteine protease initially expressed as a 40-kDa zymogen which is then converted
to its 28-kDa active form by autocatalytic truncation (5). SpeB is known to cleave host
proteins including extracellular matrix components, cytokine precursors, immunoglobulins
and antimicrobial peptides (1, 6, 7), and has been shown to play an important role in
establishing localized skin infections (8). SpeB also degrades GAS virulence factors
including the cell wall-associated fibrinogen-binding anti-phagocytic M1 protein (9, 10),
various superantigens (11, 12), and the secreted plasminogen activator streptokinase (13).

The capacity of GAS to assemble on its surface a trimolecular complex containing
streptokinase, fibrinogen, and plasminogen has been correlated with a propensity for
invasive infection (14). GAS is a highly specific human pathogen and the streptokinase
produced by this organism displays a much greater affinity for human plasminogen than
mouse plasminogen (15). A major advance in the understanding of GAS pathogenesis was

4

attained by Sun et al. (15) who established a humanized plasminogen transgenic mouse
model. These researchers demonstrated that streptokinase and the activation of
plasminogen to plasmin is critical for GAS dissemination in vivo, leading to the proposal
that human plasminogen is hijacked for use as a virulence factor by GAS (15, 16). In this
study, we utilize the representative wild-type (WT) clonal M1T1 strain 5448 and the
precise, in-frame allelic replacement mutant ∆speB (11, 17) to investigate the interplay
between SpeB and human plasminogen co-opted to the bacterial surface.
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MATERIALS AND METHODS

Strains, media and culture conditions
S. pyogenes strain 5448 (M1T1) and the isogenic ∆speB mutant have been described
previously (12). All S. pyogenes strains were routinely cultured at 37°C on horse-blood
agar (BioMérieux) or in static liquid cultures of Todd-Hewitt broth (Difco) supplemented
with 1% (w/v) yeast extract (THBY medium). When required, SpeB was inactivated by
growth in the presence of cysteine protease inhibitor E64 (N-[N-(L-3-transcarboxyirane-2carbonyl)-L-Leucyl]-agmatine) (Sigma) at a final concentration of 28 μM.

Hyaluronic acid capsule determination
Overnight cultures of S. pyogenes were diluted 1:10 in fresh THBY media and grown to an
optical density at 600 nm (OD600) of 0.5-0.6. The hyaluronic acid capsule was extracted and
quantified by the Stains-all method (18).

Preparation of culture supernatant proteins
An overnight culture of S. pyogenes was diluted 1:10 in fresh THBY medium and
incubated at 37°C to late stationary phase (approx. 16 h). The culture supernatant was
harvested by centrifugation at 8,000 × g for 20 min at 4°C and filter sterilized through a
0.22 µm filter (Millipore) for use in SpeB activity assays. For sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) analysis, equal volumes of cell-free
supernatant and 10% (v/v) trichloroacetic acid were mixed and incubated on ice for 1 h.
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Following centrifugation at 15,000 × g for 20 min at 4°C, the pellet was washed with icecold 100% ethanol and centrifuged at 15,000 × g for 15 min at 4°C. The ethanol was
removed by aspiration, the pellet air-dried for 30 min and resuspended in 1 ml of 100 mM
Tris-HCl (pH 7.6).

SpeB activity assays
Cysteine protease SpeB activity in S. pyogenes culture supernatants was determined
according to the method of Hytönen et al. (19). To examine SpeB activity of large numbers
of S. pyogenes colonies, the Columbia skim milk plate based assay was used according to
the method of Ashbaugh et al. (20).

Immunogold electron microscopy
S. pyogenes were fixed with 0.2% glutaraldehyde and 0.5% formaldehyde for 1 h on ice,
washed with cacodylate buffer (0.1 M cacodylate, 0.9 M sucrose, 0.01 M MgCl2, 0.01 M
CaCl2; pH 6.9) containing 10 mM glycine, and dehydrated with ethanol following the
progressive lowering of temperature protocol (10%, 30% ethanol on ice; 50% ethanol at –
20°C; 70, 90, 100% ethanol at –30°C; each step for 30 min). Samples were infiltrated with
the Lowicryl® resin K4M over 3 days before polymerization at –30°C with UV light (366
nm) for 2 days and 1 day at room temperature. Ultrathin sections were collected with
formvar-coated cover-slips and incubated with SpeB specific IgG antibodies (75 µg/ml, 10
h at 4°C), washed with PBS and bound antibodies were made visible with protein A/G
coated gold-particles (10 nm or 15 nm in size). Samples were counter-stained with uranyl
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acetate for 1 min and air-dried before examination in a Zeiss transmission electron
microscope EM910 at an acceleration voltage of 80 kV.

Plasminogen binding and cell surface plasmin activity
The binding of
70 ng of

125

I-plasminogen was measured as reported elsewhere (14). Approximately

125

I-plasminogen was added to 250 μl of cell suspension and incubated at room

temperature for 45 min. The cells were harvested by centrifugation, the supernatant
carefully aspirated and pellet-associated radioactivity measured using an automatic gamma
counter (Wallac). The results were expressed as a percentage of input radioactivity. All
measurements were determined in triplicate.

Plasmin acquisition in human plasma by S. pyogenes isolates was determined essentially as
described previously (21). Frozen plasma was purchased from the Red Cross Blood Bank
(Sydney, NSW, Australia), defrosted on ice and pooled. Aliquots of pooled plasma were
depleted of plasminogen by incubation at 4°C on ice with excess lysine-sepharose® 4B for
1-2 h with gentle agitation. The extent of plasminogen depletion and the plasmin activity of
plasma was determined by chromogenic assay with Spectrozyme® PL (American
Diagnostics Inc.) in the presence and absence of streptokinase, and by western blot using a
polyclonal rabbit anti-human plasminogen antibody (Calbiochem).

GAS were cultured overnight as stationary cultures in 25 ml THY inoculated with 1 colony.
GAS were pelleted by centrifugation at 800 × g, washed in 50 ml of PBS, pH 7.4
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prewarmed to 37°C, and resuspended to OD600 = 0.7 (corresponding to log phase, in which
streptokinase secretion is induced). A 2 ml aliquot of this suspension was pelleted as above,
and resuspended in an equal volume of 100% plasma or plasminogen-depleted plasma at
37°C. GAS were incubated in plasma for 3 h at 37°C, pelleted by centrifugation and
washed twice with 1 volume of ice-cold 0.01 M EDTA, 0.1% (w/v) gelatin in PBS, pH 7.4.
GAS were resuspended in 0.1% (w/v) gelatin in PBS, pH 7.4 to OD600 = 0.75. Aliquots
(100 µl) of this suspension were incubated in triplicate in the presence and absence of 20 µl
Spectrozyme® PL, 2.5 mM at 37°C for 60 min in a 96-well plate. The reaction was
quenched with 80 µl of 1.75 M acetic acid, the plates centrifuged at 800 × g and A405 of
supernatants determined.

Plasmin activity was determined as the difference between A405 in the presence and absence
of substrate, thus accounting for differences in the sedimentation efficiency of GAS
isolates. Each isolate was assayed in at least 2 independent experiments. Plasmin
equivalents and the linear range of the assay (A405 = 0 – 0.6) were determined using a
standard curve of purified plasmin (Roche Diagnostics, GmbH, Mannheim, Germany).

Extraction of cell wall-associated proteins
Mutanolysin cell-wall extracts were prepared from stationary phase cultures of S. pyogenes
as reported elsewhere (22).
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Immunological reagents
Affinity purified rabbit anti-SpeB IgG was purchased from Toxin Technology Inc.,
Sarasota, Florida, USA. Polyclonal rabbit antibodies were raised against purified
recombinant S. pyogenes streptococcal enolase (SEN) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). A rabbit polyclonal antiserum was raised against Lancefield
group C streptokinase (Sigma), which shares >90% identity with the streptokinase (Ska)
protein of S. pyogenes. All rabbit immunizations were performed according to the method
of Gillen et al. (23). The production of mouse polyclonal antiserum against M1 protein is
described elsewhere (24).

Western blot analysis
SDS-PAGE was performed according to the method of Laemmli (25). Cell wall extracts or
culture supernatant proteins were transferred to nitrocellulose membrane at 100 V for 1 h
using the Mini Trans-Blot® (Bio-Rad) (26). The membranes were blocked in a solution of
5% (w/v) skim milk (Difco) in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM
KCl, 7.9 mM Na2HPO4, 1.5 mM KH2PO4; pH 7.4) for 1 h at room temperature. After a 10
min wash with PBS, the membranes were incubated for 2 h with primary antibody diluted
1:1,000 in PBS. Following three washes for 10 min each with PBS, the membranes were
incubated for 1 h with a 1:1,000 dilution of goat anti-rabbit IgG HRP conjugate (Bio-Rad)
for SpeB, Ska, SEN and GAPDH blots, or a 1:1,000 dilution of goat anti-mouse IgG HRP
conjugate (Bio-Rad) for M1 protein blots. Excess secondary antibody was removed by
three PBS washes for 10 min each and all blots developed in a solution of 100 mM TrisHCl (pH 7.6) containing 1.4 mM diaminobenzidine and 0.06% (v/v) hydrogen peroxide.
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Protease assays
Five micrograms of SpeB protease (Toxin Technology Inc.) was mixed with 5 μg of
purified human plasminogen or fibrinogen (14), adjusted to final volume of 25 μl with PBS
(pH 7.4) and incubated at 37°C for 3 h. Cleavage of substrate protein was determined by
SDS-PAGE analysis. Positive controls containing 5 μg SpeB and 25 μg β-casein (Sigma)
were used in all assays. Negative controls containing protease or substrate only were also
included.

Streptococcal infection model
AlbPLG1 transgenic mice (Tg+) (27) heterozygous for the human plasminogen transgene
were backcrossed greater than N6 with C57BL/J6 mice (Animal Resources Centre, Perth,
Australia). Non-transgenic (Tg-) littermates were used as controls in all experiments.
Streptococcal strains used for inocula were harvested at mid-log phase (OD600 approx. 0.5).
Bacteria were washed with an equal volume of sterile 0.7% saline and diluted to the
required inoculum. The number of viable bacteria present was determined by counting
colony forming units (CFU) after plating a dilution series onto blood agar plates
(BioMérieux). Groups of 10 Tg+ mice and Tg- littermates were infected with either 2.8 ×
108 CFU (5448) or 1.35 × 108 CFU (∆speB mutant) via a subcutaneous injection into a
shaved region of the right flank of each mouse. Mortality was recorded over 14 days.
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For experiments examining the dissemination of streptococci during infection, a separate
cohort of Tg+ mice was inoculated subcutaneously. Wild type 5448 was inoculated using
1.58 × 109 CFU (n = 4; 1 mouse succumbed to infection on day 2) and 1.49 × 108 CFU (n =
1). The 5448 mutant ∆speB was inoculated using 1.71 × 109 CFU (mutant; n = 4; 1 mouse
succumbed to infection on day 2) and 4.5 × 107 CFU (n = 1). On day 3 post-infection, mice
were sacrificed by CO2 asphyxiation and representative bacteria were isolated from the site
of initial infection and bacterial loads present in the bloodstream were determined by
plating serial dilutions onto blood agar. All experiments were conducted according to the
Guidelines for the Care and Use of Laboratory Animals (National Health and Medical
Research Council, Australia) and were approved by the University of Wollongong Animal
Ethics Committee.

Statistical analyses
Average capsular hyaluronic acid, SpeB activity and plasminogen binding for 5448 and
∆speB were compared using the two-tailed unpaired t test. Cell surface plasmin activity
levels were evaluated using the Welch ANOVA (assuming unequal variances). Differences
in survival of Tg+ and Tg- mice infected with 5448 and ∆speB were determined by the logrank test. Mean bacterial loads in the bloodstream (log10 CFU) of Tg+ mice infected with
5448 or ∆speB were compared using the two-tailed unpaired t test. The t and log-rank tests
were performed using GraphPad Prism version 4.02 (GraphPad Software Inc., San Diego,
California, USA). The Welch ANOVA was performed using JMP (SAS Institute, North
Carolina, USA).
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RESULTS

Characterization of M1T1 strain 5448 and ∆speB
Both WT and isogenic ∆speB mutant strains expressed identical amounts of hyaluronic acid
capsule (Fig. 1a), excluding a pleiotropic mutation that confounded earlier studies of SpeB
in GAS pathogenesis (20). Secreted cysteine protease activity was undetectable in the
∆speB mutant (P ≤ 0.05; Fig. 1b), and SpeB zymogen was only detected at the cell wall
ExPortal microdomain (28) of the parent M1T1 strain (Fig. 1c). Nonetheless, both WT and
∆speB mutant bound equivalent amounts of purified human plasminogen (Fig. 1d). These
data indicate that, like the GAS M5 strain characterized by Rosch and Caparon (28), the
M1T1 clone also secretes SpeB zymogen via the ExPortal microdomain. The presence or
absence of SpeB does not effect the capacity of M1T1 GAS to bind purified human
plasminogen, suggesting that the surface plasminogen receptors α-enolase (SEN) (29) and
GAPDH (30) are not disabled by SpeB proteolysis. However, in comparison to the WT
strain, the isogenic ∆speB mutant accumulated 75-fold higher levels of human plasmin
activity on the bacterial surface following incubation in human plasma for 3 h at 37oC (P ≤
0.05; Fig. 1e).

Analysis of plasminogen activation system components
In order to elucidate the underlying reason(s) for the enhanced capacity of the cysteine
protease-deficient GAS strain to accumulate surface plasmin activity, we compared WT
and ∆speB mutant strains for the expression of cell wall-associated plasminogen and
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fibrinogen receptors and for secretion of streptokinase. Active 28-kDa SpeB was identified
only in supernatants of the WT strain; with addition of the SpeB inhibitor E64 just the 40kDa SpeB zymogen form was detected (Fig. 2a). Streptokinase was only present in
supernatants of the ∆speB mutant or the WT parent strain grown in the presence of E64
(Fig. 2a). The fibrinogen-binding M1 protein was found in cell wall extracts only in the
absence of SpeB activity, whereas plasminogen receptors SEN and GAPDH were detected
in cell wall extracts of both WT and ∆speB mutant (Fig. 2a). SpeB was also observed to
degrade plasminogen directly, as well as fibrinogen, which forms a trimolecular complex
with streptokinase and plasminogen bound to the GAS surface (14, 31) (Fig. 2b). Thus,
SpeB interferes with the accumulation of GAS surface bound plasmin activity by cleaving
four critical factors: plasminogen, the plasminogen activator streptokinase, fibrinogen and
the fibrinogen-binding M1 protein (16).

Infection of humanized plasminogen transgenic mice
We next took advantage of heterozygous AlbPLG1 mice that express a human plasminogen
transgene (Tg+) (15) and littermate C57BL/J6 control mice (Tg-) to examine the virulence
of WT M1T1 GAS and the isogenic ∆speB mutant in a subcutaneous infection model. Only
through use of this transgenic mouse line can one investigate the interaction of GAS with
the plasminogen activation system, since this interaction is highly specific for human
plasminogen (15, 16). In comparison to infection of non-transgenic control mice, the
virulence of WT M1T1 strain was significantly increased in Tg+ mice (P ≤ 0.05; 10% vs.
80% mortality) (Fig. 3a). This result indicates that the human plasminogen system plays a
crucial role in the ability of M1T1 GAS to initiate a lethal systemic infection.

In
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comparison to the WT GAS parent strain, the isogenic ∆speB mutant was attenuated for
virulence in the Tg+ plasminogen-humanized mice (P ≤ 0.05; 80% vs. 20% mortality) (Fig.
3a, b). Additionally, in comparison to GAS strain 5448, 72 h post-infection of Tg+ mice the
isogenic ∆speB mutant displayed significantly fewer bacterial counts in the blood (P ≤
0.05; Fig. 3c). These data support a role for SpeB in GAS survival at the site of local
infection in the skin, as proposed by Svensson et al. (8), and suggested this difference may
translate into an overall decreased lethality upon challenge with the ∆speB mutant.

To further examine the interaction between the human plasminogen system and GAS
cysteine protease SpeB, we examined the SpeB expression status of WT GAS isolated from
the blood of the infected plasminogen-humanized Tg+ mice. The WT GAS used in the
initial challenge uniformly expressed high levels of cysteine protease activity (100% of
inoculum colonies tested; n = 100). Bacteria isolated from the subcutaneous site of
infection expressed a mixed phenotype (74%, 66%, 63% and 31% of lesion recovered
colonies SpeB-negative from 4 subcutaneously inoculated Tg+ mice). Bacteria recovered
from the blood unvaryingly demonstrated very low SpeB activity (100% of blood isolated
colonies examined SpeB-negative) (Fig. 3d). This finding is consistent with the
epidemiologic observation that M1T1 clinical isolates from human invasive disease express
reduced levels of SpeB (4).
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DISCUSSION

The mechanism utilized by GAS to switch from localized to systemic infection is presently
unknown. However, subversion of the host plasminogen activation system is thought to
play a key role (15, 16). In this study, we have shown that the absence of cysteine protease
SpeB activity is required for the accumulation of plasmin activity on the cell surface of
M1T1 GAS. In a humanized plasminogen transgenic mouse model, the loss of SpeB
activity at the site of infection triggers the systemic dissemination of M1T1 GAS in vivo.
These data support the proposal that human plasminogen plays a critical role in the
initiation of GAS invasive disease.

Plasminogen is the proenzyme form of plasmin, a blood clot-dissolving serine protease
which degrades extracellular matrix components and activates matrix metalloproteases
(32). In S. pyogenes, two distinct pathways have been identified for the binding of
plasminogen to the cell surface. The direct pathway is mediated by the plasminogenbinding GAS M-like protein (PAM) (33), streptococcal enolase (SEN) (29) and GAPDH
(29, 34). Indirect plasminogen-binding requires the formation of a trimolecular complex
between plasminogen, streptokinase and fibrinogen, which is bound to the GAS cell surface
via plasminogen or fibrinogen receptors (14, 31, 35). Human plasminogen is converted to
plasmin by the plasminogen activators urokinase (uPA) and tissue-type plasminogen
activator (tPA), or by secreted microbial activators including the GAS virulence factor
streptokinase (36). Here, we demonstrate that the presence of SpeB does not interfere with
the binding of plasminogen to the GAS cell surface. However, SpeB degrades four key
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factors required for the accumulation of surface plasmin activity on the GAS surface:
plasminogen, streptokinase, fibrinogen, and the fibrinogen-binding M1 protein.

Utilizing a speB-negative mutant and a humanized in vivo model for impetigo in which
neonatal foreskin was engrafted onto the hind flanks of CB-17 scid mice, Svensson et al.
(8) determined that SpeB protease plays a critical role in the establishment of host tissue
tropism by GAS. Our accumulated data suggest that SpeB, while contributing to localized
infection, simultaneously mitigates the potential interaction of M1T1 GAS with the human
plasminogen activation system. The ablation of SpeB expression in WT M1T1 GAS in the
blood of plasminogen-humanized Tg+ mice indicates that the loss of SpeB activity in a subpopulation of bacteria occurs at the site of infection, allowing accumulation of surface
plasmin activity. This sub-population thus gain enhanced invasive propensity, favoring
transition of GAS from the site of infection to the blood. In our model, vascular leakage
induced by M protein complexing with fibrinogen to activate heparin binding protein
release from neutrophils, may provide a source of plasminogen at the site of infection (37)
(Fig. 4). The subpopulation of GAS undergoing a phase shift to eliminate SpeB expression
gain not only the capacity to accumulate cell surface plasmin activity and spread
systemically, but also elaborate greater levels of superantigens (12), the causative agents of
streptococcal toxic shock.

The expression of the streptococcal cysteine protease SpeB and human invasive disease
severity are inversely related in M1T1 clonal isolates (4). The model we propose for GAS
human systemic disease initiation accounts for this previously perplexing clinical
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observation and describes a mechanism by which systemic disease initiation occurs. The
elucidation of the mechanism by which GAS causes human invasive disease will inform
future treatment and prevention strategies.
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FIGURE LEGENDS

Figure 1. In vitro characterization of M1T1 S. pyogenes strain 5448 (WT) and the isogenic
∆speB mutant. (a) 5448 and the ∆speB mutant express equivalent amounts of capsular
hyaluronic acid (mean ± s.d.). (b) Secreted SpeB protease activity (mean ± s.d.) is
abolished in the ∆speB mutant compared with 5448. (c) Electron microscopic analyses
detected SpeB zymogen at the ExPortal microdomain of 5448, but not ∆speB (data not
shown). (d) Equivalent amounts of purified human
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I-labelled plasminogen (mean ± s.d.)

are bound by 5448 and ∆speB. (e) The ∆speB mutant cell surface accrues a 75-fold higher
level of human plasma activity (mean ± s.d.) compared with strain 5448.
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Figure 2. Western blot analysis and in vitro SpeB protease assays. (a) Blots of secreted
(SpeB, Ska and SEN) or cell wall-associated proteins (M1 and GAPDH) harvested in the
presence or absence of SpeB inhibitor E64 for 5448 (WT) and the isogenic ∆speB mutant.
Lane 1, 5448 culture supernatant or cell wall (-E64); lane 2, ∆speB culture supernatant or
cell wall (-E64); lane 3, 5448 culture supernatant or cell wall (+E64); lane 4, ∆speB culture
supernatant or cell wall (+E64). Filled arrowheads indicate major immunoreactive bands.
(b) SpeB protease degrades human plasminogen and fibrinogen, which play a key role in
the accumulation of surface-bound plasmin activity by S. pyogenes. Lane 1, SpeB; lane 2,
β-casein; lane 3, SpeB and β-casein (positive control); lane 4, plasminogen; lane 5, SpeB
and plasminogen; lane 6, fibrinogen; lane 7, SpeB and fibrinogen. Molecular mass markers
are given in kilo-Daltons (kDa).
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Figure 3. Survival curves, bacterial counts and SpeB expression phenotype following
subcutaneous infection of humanized plasminogen transgenic mice (Tg+) and nontransgenic control mice (Tg-) with S. pyogenes strain 5448 (WT) or the isogenic ∆speB
mutant. (a) The virulence of 5448 is increased in transgenic mice compared with the nontransgenic control. (b) The virulence of the ∆speB mutant was attenuated in both transgenic
and control mice. (c) Bacterial counts in the bloodstream of Tg+ mice 72 h post-infection
are significantly higher for 5448 compared with ∆speB. (d) Compared with the SpeB
activity of 5448 colonies isolated from the inoculum, the 5448 Tg+ lesion isolates exhibit a
varied SpeB-expression phenotype, while the 5448 Tg+ blood isolates have significantly
reduced SpeB activity.
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Figure 4. Proposed model for group A streptococcal systemic disease initiation. (a) S.
pyogenes M1T1 (blue) gain entry through the skin and a host innate immune response is
initiated. (b) During the initial stages of infection, S. pyogenes M1T1 express SpeB to
combat the host response. (c) Loss of SpeB activity in a sub-population of group A
streptococci (green) leads to the accumulation of surface plasmin activity. (d) Transition of
S. pyogenes M1T1 is facilitated by surface plasmin activity, resulting in systemic infection.

